ÌÇÐÄvlog´«Ã½

Single-Cell Multiomics Market Analysis

The Single-Cell Multiomics Market size is estimated at USD 3.60 billion in 2024, and is expected to reach USD 9.71 billion by 2029, growing at a CAGR of 21.95% during the forecast period (2024-2029).

Advancements in single-cell analysis technologies and products are contributing to the expansion of single-cell multiomics. The increasing use of single-cell RNA sequencing in large-scale genomics studies further drives this growth. The increasing adoption of personalized medicine for screening and diagnosing genetic disorders also promotes the growth of the single-cell multiomics market.

Various gene therapies, diagnostics, and medicines in single-cell multiomics have been introduced in recent years due to the increasing prevalence of life-threatening conditions like cancer and rare diseases. In precision medicine, multiomic strategies facilitate the integration of diverse omics data to improve the diagnosis and treatment of cancer and other chronic diseases. For instance, a report published by the National Cancer Institute in May 2024 projected that approximately 2.0 million individuals in the United States will receive a cancer diagnosis in 2024, and breast cancer is anticipated to affect 310,720 women in the country. Prostate cancer is expected to be the primary diagnosis among men and second overall, with an estimated 299,010 cases anticipated. Lung and bronchus cancer is expected to be the third most frequently diagnosed cancer, with approximately 234,580 new cases in 2024.

Similarly, the statistics from the Australia Institute of Health and Welfare published in August 2023 stated that approximately 162,000 new cancer incidences were observed in Australia in 2022, which rose to 165,000 in 2023. In addition, as per the same source, prostate, colorectal, and lung cancers were the most frequently diagnosed cancers in men. The rising incidence of cancer cases is expected to increase the demand for precision medicine for effective patient treatment, which may necessitate the use of single-cell multiomics that provide transformative insights into the clinical and molecular features of cancers. Thus, given the aforementioned factors, the market is expected to record high growth over the forecast period.

Such factors also promote collaboration between biologists, physicians, technology developers, data scientists, patient groups, and government bodies to achieve the goals of precision medicine. For instance, in November 2022, NanoString Technologies Inc. and Abcam strengthened their ongoing collaboration through a new agreement to co-market Abcam's antibodies. This partnership was aimed at enhancing the capabilities of NanoString’s high-plexity spatial and multi-omic solutions.

In October 2022, a strategic research collaboration between Illumina and AstraZeneca was announced to enhance drug target discovery through the integration of AI-based genome interpretation and genomic analysis techniques. This partnership was expected to enable AstraZeneca's Center for Genomics Research to utilize a combined AI-based framework for analyzing extensive multiomics data sets within its digital biobank. Collaborations and new program initiatives are anticipated to drive market expansion throughout the forecast period.

However, the elevated costs of single-cell analysis products and a shortage of skilled professionals are projected to impede market growth.

Single-Cell Multiomics Market Trends

The Oncology Segment is Expected to Witness High Growth Over the Forecast Period

Single-Cell Multiomics Industry Segmentation

Single-cell multiomics technologies measure various molecules from the same individual cell, providing deeper biological insights than analyzing separate molecular layers from different cells. Additionally, these technologies uncover cellular heterogeneity across multiple molecular layers within a cell population, highlighting how variations are interconnected or distinct between the captured omic layers. 

The single-cell multiomics market is segmented by type, application, end user, and geography. The type segment is further segmented into single-cell genomics, single-cell proteomics, single-cell transcriptomics, and single-cell metabolomics. By application, the market is segmented into cell biology, neurology, oncology, and other applications. The end-user segment is divided into academic & research institutes, biotechnology & pharmaceutical companies, and other end users. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for all the above segments.